Liraglutide
Liraglutide is a peptide, indexed here under Incretin receptor agonists.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Incretin receptor agonists |
| CAS registry number | 204656-20-2[1] |
| PubChem CID | 16134956[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C172H265N43O51[1] |
| Molecular weight | 3751 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Liraglutide is the oldest member of this seed set by first retrieved trial report. The retrieved literature includes a 2009 Lancet trial comparing once-daily liraglutide with twice-daily exenatide in type 2 diabetes, a 2016 New England Journal of Medicine report on cardiovascular outcomes, and a 2017 report on renal outcomes in the same population.
Weight and hepatic endpoints appear in a 2015 New England Journal of Medicine randomised controlled trial of 3.0 mg of liraglutide in weight management and a 2016 Lancet report in non-alcoholic steatohepatitis. The 2024 BMJ network meta-analysis places the compound among the GLP-1 receptor agonists compared on glycaemic control, body weight and lipid profile.
[3, 4, 5, 6, 7, 8]Reported mechanism
Agonist at the glucagon-like peptide-1 receptor.
[9, 8]Derived: the receptor mechanism is taken from the cited 2024 GLP-1 receptor review, and this compound is placed in that class by the cited 2024 BMJ network meta-analysis of GLP-1 receptor agonists. No retrieved title for this compound states the receptor directly.
Targets named in the cited records: GLP-1 receptor.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 11 application record(s) for this compound name (including ANDA214568, ANDA217063, ANDA215421, NDA022341, ANDA217590, marketed as LIRAGLUTIDE, VICTOZA). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
| Reported in | Amount reported | Study model |
|---|---|---|
| [6] | 3 mg | human trial |
Every row states what a named study reported in its own stated model. Nothing in this table is an instruction, a protocol or a recommendation.
Literature-reported only. Describes what the cited study administered in its stated model. Not a protocol and not a recommendation.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Liraglutide appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- NN2211
- NNC 90-1170
Where this page sits
Research records
Cited research records for Liraglutide, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Side-by-side pages that include Liraglutide
Compounds indexed next to it
- Semaglutide — Incretin receptor agonists
- Tirzepatide — Incretin receptor agonists
- Dulaglutide — Incretin receptor agonists
- Exenatide — Incretin receptor agonists
- Lixisenatide — Incretin receptor agonists
- Retatrutide — Incretin receptor agonists
Named targets in the cited records
Class page: Incretin receptor agonists. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Liraglutide?
Liraglutide is the oldest member of this seed set by first retrieved trial report. The retrieved literature includes a 2009 Lancet trial comparing once-daily liraglutide with twice-daily exenatide in type 2 diabetes, a 2016 New England Journal of Medicine report on cardiovascular outcomes, and a 2017 report on renal outcomes in the same population.
Which class is Liraglutide indexed under?
Liraglutide is indexed under Incretin receptor agonists. Incretin receptor agonists are synthetic peptides that bind one or more of the incretin and glucagon family receptors, principally the glucagon-like peptide-1 receptor.
What does the FDA application register show for Liraglutide?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 11 application record(s) for this compound name (including ANDA214568, ANDA217063, ANDA215421, NDA022341, ANDA217590, marketed as LIRAGLUTIDE, VICTOZA). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.
Sources
- PubChem Compound Summary for CID 16134956, Liraglutide. PubChem, National Library of Medicine (2026). pubchem:16134956
- Drugs@FDA application register query for this compound, 11 application(s) returned: ANDA214568, ANDA217063, ANDA215421, NDA022341, ANDA217590. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:liraglutide
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet (2009). pmid:19515413
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2016). pmid:27295427
- Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med (2017). pmid:28854085
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med (2015). pmid:26132939
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet (2016). pmid:26608256
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ (2024). pmid:38286487
- Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther (2024). pmid:39289339
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.